Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1825552 | 0.89 | POLB (0.52) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1822709 | 0.89 | MRGPRX4 (0.68) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1828333 | 0.87 | PKM (0.47) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1824562 | 0.87 | MRGPRX4 (0.60) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1826216 | 0.85 | MRGPRX4 (0.51) | MRGPRX4KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1825782 | 0.85 | MRGPRX4 (0.56) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1825881 | 0.84 | MRGPRX4 (0.53) | MRGPRX4KDM4EMAPTPKM | |
| SCHEMBL1827353 | 0.84 | MRGPRX4 (0.58) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1825488 | 0.80 | THRA (0.52) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1825789 | 0.80 | THRA (0.49) | MRGPRX4KDM4EMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | claimed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | claimed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | claimed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | claimed |
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | claimed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | disclosed |
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | MRGPRX4 1127/4885KDM4E 4207/4885MEN1 1718/4885 |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | MRGPRX4 1135/4885KDM4E 4172/4885MEN1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.